Santa Clara, CA, United States of America

Randall A Scheuerman

This inventor holds 20 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 1 EPO patent, primarily in Pharmaceutical Chemistry. Top assignees: Xenoport, Inc., Syngenta Participations Ag, Affymax, Inc.. Active years: 2001-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Randall A Scheuerman. Retrieved from https://idiyas.com/inventor/randall-a-scheuerman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 20 (Patent Applications = 1)

% Patents Active = 65.0

CIPO Patents = 1

EPO Patents = 1 (Patent Applications = 3)

Average Co-Inventor Count = 4.0

ph-index = 5

Forward Citations = 113(Granted Patents)

Company Filing History:

Syngenta Participations Ag

Years Active: 2001-2018

Loading Chart...

Areas of Expertise:

Prodrug Synthesis

GABA Analogues

Oxidation Process

Amino Acid Conjugates

Levodopa Ester

Carbamate Prodrugs

Hormone Antagonists

Synthesis Methods

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9895336 - Crystalline forms of (N, N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use (2018-02-20),

2. 9795581 - Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use (2017-10-24),

3. 9682057 - Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use (2017-06-20),

4. 9533941 - Methods of synthesizing a levodopa ester prodrug (2017-01-03),

5. 9416096 - Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use (2016-08-16),

6. 9353057 - Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof (2016-05-31),

7. 9302977 - Method of making monomethyl fumarate (2016-04-05),

8. 9290445 - Methods of synthesizing a levodopa ester prodrug (2016-03-22),

9. 8378137 - Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof (2013-02-19),

10. 8003809 - Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof (2011-08-23),

11. 7767649 - Amino acid conjugates providing for sustained systemic concentrations of GABA analogues (2010-08-03),

12. 7645797 - Amino acid conjugates providing for sustained systemic concentrations of GABA analogues (2010-01-12),

13. 7511158 - Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof (2009-03-31),

14. 7420002 - Amino acid conjugates providing for sustained systemic concentrations of GABA analogues (2008-09-02),

15. 7227028 - Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof (2007-06-05),

Title: Innovations of Randall A Scheuerman: A Pioneer in Pharmaceutical Patents

Introduction

Randall A Scheuerman is an accomplished inventor based in Santa Clara, California. With a prolific portfolio of 20 patents, he has made significant contributions to the field of pharmaceuticals, particularly in the development of prodrugs and their applications.

Latest Patents

His recent inventions include crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, which serves as a prodrug of methyl hydrogen fumarate. Scheuerman has disclosed several crystalline forms including Crystalline form 1, Crystalline form 2, Crystalline form 3, and Crystalline form 4, along with methods of synthesis and use, highlighting his commitment to advancing medicinal chemistry.

Career Highlights

Throughout his career, Randall has worked with notable organizations such as Xenoport, Inc. and Syngenta Participations AG. His experience in these companies has undoubtedly shaped his expertise and innovation in the pharmaceutical sector.

Collaborations

Scheuerman has collaborated with esteemed colleagues like Mark A Gallop and Stephen P Raillard, sharing insights and driving advancements in their respective fields.

Conclusion

Randall A Scheuerman stands out as a prominent inventor in the pharmaceutical industry. His contributions, evidenced by his patents and collaborative efforts, continue to influence the development of new therapeutic applications.

Profile summary based on public USPTO records.